CJC-1295 Ipamorelin Dosage in the Research Literature

Dose Ranges Studied in Preclinical and Human Protocols

CJC-1295 ipamorelin dosage parameters in the published literature span a wide range by species, route, and study objective. No CJC-1295/ipamorelin combination dosing study in humans has been published; the human dose data for CJC-1295 come from the Phase I/II-context single-compound trials, and the ipamorelin dose data come primarily from rat and swine preclinical studies and Phase I human safety data.

CJC-1295 (with DAC) in human studies: Ionescu and Frohman (2006) studied doses of 60 µg/kg and 90 µg/kg via subcutaneous injection in healthy men, producing 46% mean GH elevation and 45% IGF-1 elevation at one week ^[1]. The proteomic downstream study (Sackmann-Sala et al. 2009) used the same dose range ^[6]. A ClinicalTrials.gov study (NCT00267527) evaluated CJC-1295 in HIV patients with visceral obesity; primary results were not published in peer-reviewed literature.

CJC-1295 in rodent studies: Alba et al. (2006) administered 2 µg/day to GHRH-knockout mice, normalizing body weight, length, lean mass, and subcutaneous fat mass ^[5].

Ipamorelin in rat studies: Johansen et al. (1999) studied dose-dependent series via subcutaneous injection for 15-day bone-growth protocols ^[4]. Andersen et al. (2001) administered 100 µg/kg three times daily subcutaneous for glucocorticoid-counteraction studies ^[8]. Svensson et al. (2000) used 0.5 mg/kg/day for 12-week bone mineral content studies ^[9]. Venkova et al. (2009) administered 0.01–1 mg/kg IV four times daily for GI motility restoration ^[10].

These doses are research-context parameters. None constitute clinical guidance for human use.

CJC-1295 and Ipamorelin Half-Life

CJC-1295 without DAC approximates the pharmacokinetic profile of native GRF(1-29), which has a plasma half-life below 10–13 minutes due to rapid DPP-IV N-terminal cleavage ^[16]. CJC-1295 with the DAC albumin-bioconjugation modification has a plasma half-life of approximately 6–8 days in humans, confirmed by the sustained IGF-1 elevation persisting beyond 14 days from a single dose in human Phase I/II-context data ^[1] and by plasma detection beyond 72 hours post-single-subcutaneous-dose in rats ^[2].

Ipamorelin's plasma half-life in rodents is approximately 2 hours, estimated from pharmacokinetic excretion studies showing 5-fold lower plasma clearance than GHRP-6 and 60–80% of administered dose recoverable as intact peptide from bile and urine ^[7]. No formally published human pharmacokinetic data exist for ipamorelin's half-life in vivo.

What is the half-life of CJC-1295 and ipamorelin? In summary: CJC-1295 without DAC — below 30 minutes (DPP-IV-limited, analogous to native GHRH); CJC-1295 with DAC — approximately 6–8 days (albumin-bound); ipamorelin — approximately 2 hours in rodent models (no validated human data published).

Injection Frequency in Study Protocols

Research protocols vary by compound form and study objective. CJC-1295 with DAC has been studied at once-weekly or less frequent dosing intervals in human Phase I/II-context studies, consistent with its multi-day half-life ^[1]. CJC-1295 without DAC has been proposed in research settings at once-to-twice daily subcutaneous injection based on its shorter half-life approximating native GRF(1-29), though published data for this dosing frequency in human subjects are limited.

Ipamorelin has been studied at 1–3 daily doses in animal models: three-times-daily subcutaneous injection was the primary protocol in the bone formation and glucocorticoid-counteraction studies ^[8], and four-times-daily IV dosing was used in GI motility protocols ^[10]. How often should you inject CJC ipamorelin? Published preclinical protocols typically specify multiple daily ipamorelin doses given the approximately 2-hour rodent half-life, combined with less frequent CJC-1295 dosing determined by the DAC vs no-DAC form used in the study. Human combination protocols have not been published in peer-reviewed literature.

Fasting State and Injection Timing in Study Protocols

Research protocols typically specify fasted-state administration to minimize somatostatin-mediated GH blunting. Food intake elevates insulin; elevated insulin triggers hypothalamic somatostatin release; somatostatin suppresses pituitary GH secretion, reducing the GH pulse amplitude produced by GHRH-axis or ghrelin-axis stimulation. In a 5-day fast study in men, GH pulse frequency increased from 5.8 to 9.9 pulses per 24 hours (p=0.028) and 24-hour GH concentration rose from 2.82 to 8.75 µg·min/mL (p=0.0002), with elevated free fatty acids and reduced insulin identifying somatostatin suppression as the primary mechanism ^[11]. Should CJC-1295/ipamorelin be taken fasted or with food? Published research on GH pulsatility and food intake supports the inference that fasted administration is standard in GH secretagogue research protocols, though direct CJC-1295/ipamorelin timing trials in humans have not been published.

The circadian link between slow-wave sleep (SWS) and the largest endogenous GH pulse of the day is a relevant timing context: the peak GH pulse typically coincides with the first SWS period. Ghrelin administration to human subjects (4 × 50 µg IV boluses over 3 hours) enhanced slow-wave sleep and delta-wave activity ^[12], suggesting ghrelin-receptor agonism may amplify the nocturnal GH/sleep coupling. This finding — from ghrelin rather than ipamorelin directly — provides a mechanistic basis for the pre-sleep injection timing used in some research protocols, though timing protocols for ipamorelin specifically in human subjects have not been published.

Time Course of Effects in Research Models

CJC-1295 produced sustained GH elevations detectable within hours of injection in human Phase I/II-context trials; IGF-1 elevation was confirmed at one week post-dose ^[1]. Sustained IGF-1 elevation persisted for up to 28 days post-dose with the DAC form based on published follow-up intervals. Ipamorelin's acute GH pulse peaks approximately 15–30 minutes post-injection in rodent models based on GH secretagogue pharmacodynamic literature, consistent with its ~2-hour half-life and GHS-R1a pulsatile-release mechanism.

How long do CJC and ipamorelin take to work? For the GH-axis endpoints: CJC-1295 human data show measurable GH and IGF-1 elevation within the first week; downstream biological endpoints (body composition, bone mineral content, metabolic changes) have been characterized over 4–12 weeks in animal model studies. CJC-1295 Phase II trials with the DAC form showed IGF-1 elevation within 2 weeks. Body composition endpoints in animal studies showed measurable changes at 4–8 weeks ^[4][8][9].

Reconstitution and Handling in Research Settings

Lyophilized peptide vials are typically reconstituted with bacteriostatic water (0.9% benzyl alcohol) in research settings. How to reconstitute CJC-1295 ipamorelin 5mg? Standard reference protocols add bacteriostatic water slowly down the vial wall — not directly onto the lyophilized pellet — to avoid agitation-induced aggregation that accelerates peptide degradation.

Reconstituted aqueous peptide solutions degrade via asparagine deamidation; degradation products may be 25–500-fold less potent than intact peptide. The stability note in the research literature specifies lyophilized vials stable at −20°C for months; reconstituted solutions stored at 2–8°C should be used within the window specified by the peptide stability characterization data. Agitation accelerates aggregation and should be avoided. GRF analogs including CJC-1295 undergo DPP-IV cleavage in plasma; the DAC form was engineered specifically to resist this pathway, but reconstituted solution stability precedes in vivo metabolism and is a handling concern independent of the DAC modification. CJC-1295 ipamorelin reconstitution protocols in peer-reviewed laboratory methods specify gentle mixing and cold-chain storage.